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Angiogenesis contributes to various pathological conditions.
Due to the resistance against existing antiangiogenic therapy, an
urgent need exists to understand the molecular basis of vessel
growth and to identify new targets for antiangiogenic therapy.
Here we show that cyclin-dependent kinase 5 (Cdk5), an impor-
tantmodulator of neuronal processes, regulates endothelial cell
migration and angiogenesis, suggesting Cdk5 as a novel target
for antiangiogenic therapy. Inhibition or knockdown of Cdk5
reduces endothelial cell motility and blocks angiogenesis in
vitro and in vivo.We elucidate a specific signaling of Cdk5 in the
endothelium; in contrast to neuronal cells, the motile defects
upon inhibition of Cdk5 are not caused by an impaired function
of focal adhesions ormicrotubules but by the reduced formation
of lamellipodia. Inhibition or down-regulation of Cdk5 de-
creases the activity of the small GTPase Rac1 and results in a
disorganized actin cytoskeleton. Constitutive active Rac1 com-
pensates for the inhibiting effects ofCdk5knockdownonmigra-
tion, suggesting that Cdk5 exerts its effects in endothelial cell
migration via Rac1. Our work elucidates Cdk5 as a pivotal new
regulator of endothelial cell migration and angiogenesis. It sug-
gests Cdk5 as a novel, pharmacologically accessible target for
antiangiogenic therapy and provides the basis for a new thera-
peutic application of Cdk5 inhibitors as antiangiogenic agents.
Angiogenesis is involved in various pathological conditions,
including arthritis, psoriasis, diabetic retinopathy, macula
degeneration, and cancer (1). During recent years, the search
for antiangiogenic compounds and their molecular targets has
been intensified. Due to its key role in angiogenesis, research
initially focused on vascular endothelial growth factor (VEGF).
VEGF receptor inhibitors such as the monoclonal antibody
bevacizumab (Avastin) as well as VEGF tyrosine kinase inhib-
itors such as sunitinib (Sutent) or sorafenib (Nexavar) have
been approved for cancer therapy. Unfortunately, the benefits
of these therapeutics are at best transitory and mostly followed
by a restoration of tumor growth and progression (2). This
resistance to antiangiogenic therapy causes a great need for new
targets to inhibit vessel growth, interfering with steps in the
angiogenic cascade different from the response to a single
growth factor.
Cyclin-dependent kinase 5 (Cdk5) is a small serine/threonine
kinase belonging to the family of Cdks. In contrast to the cell
cycle-related Cdks (e.g. Cdks 1, 2, 4, or 6), Cdk5 is not impli-
cated in cell cycle control (3). Instead, it is an important regu-
lator of neuronal development, and it controls various pro-
cesses in postmitotic neurons (4). Although it is expressed
ubiquitously, so far, just a few reports indicate a function of
Cdk5 beyond the nervous system. Scarcely anything is known
about a potential function of Cdk5 in the vasculature, and its
exact functions and signaling mechanisms in the endothelium
remain unknown (5–8).
Our aim was to close this gap of knowledge. This is the first
study that describes the function of Cdk5 in the endothelium. It
focuses on endothelial cellmigration and angiogenesis and pro-
vides the first information concerning the signalingmechanism
of endothelial Cdk5.
EXPERIMENTAL PROCEDURES
Cell Culture
HUVECs2were prepared by digestion of umbilical veins with
collagenase A as described previously and cultured in endothe-
lial cell growth medium (ECGM, Provitro, Berlin, Germany)
(9). Umbilical cords were collected from local hospitals in
accordance with the declaration of Helsinki. Roscovitine was
from Sigma-Aldrich.
Migration Assay
Confluent HUVECs were scratched with a pipette tip and
treated as indicated. After 16 h, cells were fixed with 3% form-
aldehyde, and images were taken using the TILLvisION system
(Lochham, Germany) connected to an Axiovert 200 micro-
scope (Zeiss, Germany). Evaluation of pictures was made by
S.CO LifeScience (Garching, Germany). Migration was quanti-
fied as the ratio of the area coveredwith cells and the area of the
cell-free wound. Experiments with the proliferation inhibitor
5-hydroxyurea were performed to exclude an influence of anti-
proliferative effects in the scratch assay in our setting.
□S The on-line version of this article (available at http://www.jbc.org) contains
supplemental videos 1–5.
1 To whom correspondence should be addressed: Center for Drug Research,
Pharmaceutical Biology, Ludwig-Maximilians-University, Butenandtstr.
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77170; E-mail: stefan.zahler@cup.uni-muenchen.de.
2 The abbreviations used are: HUVEC, human umbilical vein endothelial cell;
ECGM, endothelial cell growthmedium; nt, non-targeting; FAK, focal adhe-
sion kinase; ROCK, Rho-associated protein kinase; 5-HU, 5-hydroxyurea;
ANOVA, analysis of variance; DMSO, dimethyl sulfoxide; rosc, roscovitine.
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Chemotaxis Assay
Cells were seeded into -Slide chemotaxis (ibidi GmbH,
Munich, Germany). After 4 h, an FCS gradient from 0% FCS
to 10% FCS was generated, according to the manufacturer’s
protocol. Images were obtained with a Zeiss LSM 510META
confocal microscope and the appropriate LSM software. The
objective used was a Ph1-NEOFLUAR 10/0.30. A heating
stage from EMBLem (Heidelberg, Germany) was used to
keep cells at 37 °C and 5% CO2. Images of cells have been
obtained for 20 h.
Tube Formation Assay
1  104 HUVECs in ECGM containing roscovitine were
seeded onto Matrigel (Schubert & Weiss-OMNILAB,
Munich, Germany)-coated ibidi angiogenesis-slides (ibidi
GmbH). After 16 h, images were taken using the TILLvisION
system. Evaluation of pictures was performed by S.CO Life-
Science. Tube length (displayed in red in Fig. 2) was
analyzed.
Chorioallantoic Membrane Assay
Fertilized white leghorn chicken eggs (Lohmann Tierzucht,
Cuxhaven, Germany) were incubated at 37 °C for 72 h with
constant humidity. Eggs were transferred into dishes (ex ovo),
incubated for further 72 h, and stimulated with VEGF (1
ng/disk) alone or with VEGF and roscovitine (45 g/disk)
using small cellulose disks. The next day, chorioallantoic
membranes were photographed using a stereomicroscope
(Olympus, Munich, Germany).
Mouse Aortic Ring Assay
Mouse aortic rings were embedded into Matrigel. Once
endothelial cell sprouting occurred, rings were treated with
either ECGM or ECGM containing roscovitine. After 72 h,
images were taken using the TILLvisION system.
CorneaMicropocket Assay
Both eyes of C57BL/6J 8-week-old female mice were
implanted with pellets containing basic FGF (80 ng/pellet)
as described previously (10, 11). Starting at the time of sur-
gery, mice (20–21 g of body weight) were injected daily with
either DMSO (control) or roscovitine for 5 days. For each
application, 200 l of the solutions were injected intraperi-
toneally, and mice received 100 mg/kg of body weight of
roscovitine each time. On postoperative day 6, vasculariza-
tion was quantified. Vessel length (VL) and clock hours (CH)
were measured, and the vascularized area (VA) was calcu-
lated as 1/2  VL  0.4 CH. The study complies with the
FIGURE 1. Cdk5 is expressed in the endothelium in vivo. Images display the staining of Cdk5 (red) and VE-cadherin (green) in a human umbilical cord. The
lower panels show the area marked by the squares in the upper panels in higher magnification. The merged images show the overlay of the two channels
(yellow), demonstrating the localization of Cdk5 to the endothelium.
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Guide for the Care and Use of Lab-
oratory Animals published by the
United States National Institutes
of Health (47) and with local
regulations at the University of
Debrecen.
Transfection
Cdk2 and Cdk5 siRNA—2  106
HUVECs were transfected with
3.0 g of ON-TARGETplus Cdk2
siRNA (1.5 g of J-003236-1, 5-
PUAUUAGGAUGGUUAAGCU-
CUU-3, and 1.5 g of J-003236-
12, 5-PUCUCCCGUCAACUUG-
UUUCUU-3; Dharmacon, Lafay-
ette, CO) or 3.0 g of ON-
TARGETplus Cdk5 siRNA (1.5 g
of J-003239-09, 5-PACAUCGG-
AUAGGGCUUAUAUU-3, and
1.5 g of J-003239-10, 5-PGAU-
CUCAUGAGUCUCCCGGUU-3),
respectively, by electroporation
with the NucleofectorTMII (Amaxa,
Cologne, Germany) according to
the manufacturer’s protocol. For
transfection control, HUVECs
were transfected with 3.0 g of
ON-TARGETplus non-targeting
siRNA (nt siRNA) (D-001810-
01, 5-UGGUUUACAUGUCG-
ACUAA-3). Silencing of Cdk2
and Cdk5 was examined by West-
ern blot analysis.
Cdk5 shRNA—Adenoviral trans-
duction of HUVECs with Cdk5
shRNA and nt shRNA was per-
formed by SIRION BIOTECH
GmbH (Munich, Germany). Knock-
down of Cdk5 was examined by
Western blot analysis.
Rac V12—Co-shRNA-treated
HUVECs or Cdk5 shRNA-treated
HUVECs were transfected with
2 g of Rac V12 (A. Go¨rlach,
Munich, Germany) or pcDNA3
(Molecular Probes/Invitrogen, Karls-
ruhe, Germany). 12 h after transfec-
tion, scratch assays were performed.
Transfection efficiencywas examined
byWestern blot analysis.
Cdk5 Overexpression—HUVECs
were transfected with 3 g of
wild-type Cdk5 (Cdk5-wt) or a
dominant-negative Cdk5 mutant
Cdk5-D145N (Cdk5-dn, Addgene,
Cambridge, MA; numbers 1871
and 1873, S. van den Heuvel).
FIGURE 2. Inhibition of Cdk5 reduces angiogenesis in vitro. A, inhibition of Cdk5 by roscovitine (rosc)
decreases endothelial cell migration (Kruskal-Wallis one-way ANOVA on ranks, *, p  0.05, n  4; upper
panels). Treatment with 5-HU (2 mM) alone had no effect on HUVEC migration and did not alter the
migration-inhibiting effect of roscovitine (Student’s t test, *, p 0.001; n 5; lower panel). B, inhibition of
Cdk5 disturbs chemotaxis of HUVECs. Untreated cells (co) move along the FCS gradient (0–10%, upper left
panel). rosc at 10 M inhibits cell orientation (upper middle panel) and reduces cell motility at 30 M (upper
right panel), respectively. Cells migrating in the direction of the FCS are shown in black, and cells migrating
in other directions are in red (one-way ANOVA/Dunnett’s test, *, p  0.05, n  3). C, inhibition of Cdk5
reduces endothelial tube formation. The images in the upper panel show tube formation of cells with or
without rosc (16 h). Tube structures identified by the software are displayed in red, and quantitative
evaluations are displayed in the lower panels. rosc (16 h) reduces tube length, and treatment with 5-HU (2
mM, 16 h) had no effect. Tube formation is reduced upon inhibition of Cdk5 after 4 h, excluding the effects
of roscovitine on cell proliferation (roscovitine, 16 h, one-way ANOVA/Dunnett’s test, *, p  0.05, n  3;
5-HU, 16 h, Kruskal-Wallis one-way ANOVA on ranks, *, p 0.05, n 4; roscovitine, 4 h, one-way ANOVA/
Dunnett’s test, *, p  0.05, n  4). n.s., not significant.
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pCMV-neo-Bam (3 g, Addgene, number 16440, B.
Vogelstein) was used as a control. 24 h after transfection,
scratch assays ware performed. Transfection efficiency was
examined by Western blot analysis.
CellTiter-Blue Cell Viability Assay
Transfected cells were seeded into 96-well plates (2  104
cells/well) for 24 h. CellTiter-Blue assay was performed
according to the manufacturer’s protocol (Promega Corp.,
FIGURE 3. Inhibition of Cdk5 reduces angiogenesis ex vivo and in vivo. A, inhibition of Cdk5with rosc inhibits endothelial cell sprouting frommouse aortic
rings. co indicates mice treated with solvent (DMSO). B, inhibition of Cdk5 abolishes VEGF-induced vessel formation in the chorioallantoic membrane assay.
Circles represent localization of cellulose disks containing VEGF (1 ng/disk) or VEGF combinedwith rosc (45g/disk) (n 3). C, inhibition of Cdk5 reduces basic
FGF-induced neovascularization in themouse corneamicropocket assay. The growth of blood vessels into the pellet containing basic FGF inmice treatedwith
solvent (DMSO, co) is shown in theupper left panel. Theupper right panel indicates one eyeof amouse injected intraperitoneallywith rosc (100mg/kg/day). The
graph (lower panel) represents the quantitative evaluation of the vascularized area (Student’s t test corrected for unequal variances, p 0.00018, n 10 for
control, n 16 for roscovitine).
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FIGURE4.Cdk5 is implicated intheregulationofendothelial cellmigration.A, silencingofCdk5withsiRNA(Cdk5siRNA) reducesendothelial cellmigration;Cdk2
siRNAhasno influence,andntsiRNAservesascontrol (one-wayANOVA/Dunnett’s test, *,p0.05,n5).B, Cdk2andCdk5aresuccessfullydown-regulated24hafter
treatmentwith siRNA; nt siRNA serves as control, and-actin indicates equal loading.C, Cdk5 siRNAdoesnot influence cell viability (Student’s t test,p0,974,n4).
D, endothelial cellmigration is reduced upondown-regulation of Cdk5with shRNA; nt shRNA serves as control (Student’s t test, *, p 0,001, n 5). E, knockdownof
Cdk5 inhibits endothelial cell chemokinesis. Cells treatedwith nt shRNAmove along the FCS gradient (0–10%, left panel). Cdk5 shRNA inhibits cell orientation (right
panel). Cells migrating in the direction of FCS are shown in black, and cells migrating in other directions are in red. The quantitative evaluation of cumulative and
euclideandistances isdisplayed in the lowerpanels (Student’s t test, *,p0.05,n4).F, theWesternblot indicates successful knockdownofCdk5by shRNA;nt siRNA
serves as control, and -actin indicates equal loading. G, kinase activity of Cdk5 is required for endothelial cell migration. Scratch assays of HUVECs overexpressing
wild-typeCdk5(Cdk5-wt)ordominant-negativeCdk5(Cdk5-dn) areshown.Cells transfectedwithpCMV-neo-Bam(emptyvector (co))wereusedascontrol.Dominant-
negative Cdk5 significantly decreases HUVECmigration (one-way ANOVA/Holm-Sidak, *, p 0.05, n 4).
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Madison, WI). Fluorescence was measured at 560 nm using a
TECAN SPECTRAFluor Plus fluorescence, absorbance, and
luminescence reader (MTX Lab Systems, Inc., Crailsheim,
Germany).
Western Blot Analysis
Western blot analysis was performed as described previously
(12). Antibodies against Cdk5 were from Molecular Probes/
Invitrogen, antibodies against focal adhesion kinase (FAK) and
FAK phospho-Tyr-397 were from Santa Cruz Biotechnology
(SantaCruz, CA), antibodies against
p27kip1 and FAK phospho-Ser-732
were from BIOSOURCE (Cam-
arillo, CA), and the antibody against
Myc tag was from Cell Signaling
(Danvers, MA). Alexa Fluor 680
goat-anti-mouse and Alexa Fluor
800 goat-anti-rabbit were used as
secondary antibodies (Molecular
Probes/Invitrogen). For detection,
anOdyssey infrared imaging system
(Li-Cor Biosciences, Lincoln, NE)
was used.
Adhesion Assay
HUVECs were trypsinized and
suspended in ECGMor ECGMcon-
taining roscovitine (30M), and 1
106 cells/well were plated in 24-well
plates, which were either left un-
coated or coated with fibronectin
(25 g/ml), collagen (0.001% in
PBS) orMatrigel (10% in serum-free
medium) After 30 min, cells were
stained with crystal violet, and
absorption was measured using the
TECAN SPECTRAFluor Plus fluo-
rescence, absorbance, and lumines-
cence reader.
Confocal Laser Scanning
Microscopy
Primary antibodies against Rac1
(Millipore, Billerica, MA) and cor-
tactin (Cell Signaling Technology,
Denver, MA) were diluted 1:100 in
PBS containing 0.2% BSA. F-actin
was stained with rhodamine/phal-
loidin (1:400, R 415, Molecular
Probes/Invitrogen).
For live cell imaging, cells were
transfected with the indicated plas-
mids, and experiments were started
24 h (eGFP-Cdk5) or 48 h (YFP-
Rac1, eGFP-CLIP-170, eYFP-vincu-
lin) after transfection, respectively.
eGFP-CLIP-170 was kindly pro-
vided by N. Galjart (Rotterdam, The
Netherlands), eYFP-vinculin was provided by A. Bershadsky
(Rehovot, Israel), eYFP-Rac1 was from ATCC/Promochem
(Wesel, Germany), and eGFP-Cdk5 was from Addgene (Cam-
bridge, MA; number 1346, L.-H. Tsai). Images were obtained
with a Zeiss LSM 510 META confocal microscope and the
appropriate LSM software.
Tubulin Fractionation
Cells were treated as indicated for 4 h and lysed using lysis
buffer containing Pipes (100 mM), glycerol (2 M), Triton-X-100
FIGURE 5.Cdk5does not influence cell adhesion andmicrotubules. A, roscovitine decreases the phosphor-
ylation of FAK at Ser-732; the phosphorylation of FAK at Tyr-397 is not influenced. B, Cdk5 siRNA reduces the
phosphorylation of FAK specifically at Ser-732. C, Cdk5 inhibition does not influence the size, localization, and
dynamics of focal adhesions. co indicates the absence of rosc. D, rosc (30M) does not influence the adhesion
of cells on differentially coated surfaces (Student’s t test, n 3). E, microtubule structure is not changed by
Cdk5 inhibition. F, Cdk5 inhibition does not influence the dynamics of microtubules. Representative
images show HUVECs expressing eGFP-CLIP-170 during migration in the absence (co) or presence of rosc
(30 M) (n 2). G, rosc (30 M) does not influence the polymerization of tubulin. Taxol (T) and vinblastine
(VB) show the expected stabilization or fragmentation of microtubules, respectively. Fractions of poly-
merized tubulin are shown (n  3).
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(0.5%),MgCl2 (2mM), EGTA (2mM), taxol (5M), GTP (1mM),
phenylmethylsulfonyl fluoride (PMSF) (1 mM), and Complete
protease inhibitor (Roche Applied Science) (4%). Lysates were
centrifuged (45 min, 47,000 rpm), and the supernatant was
mixed with 3 Laemmli sample buffer and boiled for 5 min.
The pellet was incubated with 40l of a buffer containing Tris/
HCl (100 mM), MgCl2 (1 mM), and CaCl2 (10 mM) at 4 °C for 60
min, mixed with 3 Laemmli sample buffer, and boiled for 5
min.Western blot analysis was performed using anti--tubulin
antibody (Santa Cruz Biotechnology).
Pulldown Assay
Cells were treated as indicated and plated for 30 min. Pull-
down assays were performed according to the manufacturer’s
protocol (Rho activation assay kit 17-294 and Rac1 activation
assay kit 17-441, both fromMillipore, Billerica, MA).
Statistical Analysis
The number of independently performed experiments and
the statistical tests used are stated in the respective figure leg-
ends.Graphdata representmeans S.E. Statistical analysiswas
performed with the SigmaStat software Version 3.1 (SYSTAT
Software, Inc., Point Richmond, CA). Statistical significance is
assumed if p 0.05.
RESULTS
Cdk5 Is Expressed in the Endothelium—To demonstrate the
presence of Cdk5 in the endothelium in situ, human umbilical
cords were stained for Cdk5 (red) together with VE-cadherin
(green), which was used as endothelial marker (Fig. 1). As
expected, Cdk5, which is expressed
ubiquitously (4), localizes to all tis-
sues in the human umbilical cords.
Merged images clearly show the
expression of Cdk5 in the endothe-
lium (overlay of Cdk5 and VE-cad-
herin, yellow).
Inhibition of Cdk5 with Roscovi-
tine Disrupts Angiogenesis—The
impact of inhibition of Cdk5 on
angiogenesis was examined by per-
forming various functional angio-
genesis assays in vitro and in vivo
using the Cdk5 inhibitor roscovi-
tine. Inhibition of Cdk5 by roscovi-
tine significantly reduced endothe-
lial cell migration by 20% (10 M)
and 67% (30 M), respectively (Fig.
2A, upper panel). Possible false pos-
itive results due to antiproliferative
effects have been excluded by using
5-hydroxyurea (5-HU), an inhibitor
of proliferation. Treatment with
5-HU alone did not influence
wound closure, and the migration-
inhibiting effect of roscovitine was
not altered in the presence of 5-HU
(Fig. 2A, lower panel). Chemotaxis
assays revealed that untreated cells moved along an FCS
(0–10%) gradient (Fig. 2B, upper left panel). Cells treated with
10 M roscovitine still moved (indicated by an intact cumula-
tive distance) but did not follow the FCS gradient, suggesting a
loss of orientation (indicated by a reduced euclidean distance).
Roscovitine at a concentration of 30 M reduced both cumula-
tive and euclidean distance, reflecting a completely defective
motility (Fig. 2B, lower panels). Applying tube formation assays,
untreated cells formed three-dimensional structures. In con-
trast, tube formation of roscovitine-treated cells was reduced
significantly after 16 h. Again, the antiangiogenic effects of
roscovitine are not caused by an inhibition of proliferation. The
treatment with 5-HU (16 h) had no effect on tube formation,
and roscovitine significantly reduced tube length already after
4 h treatment (Fig. 2C). Supplemental video 1 shows cells
seeded on Matrigel for 16 h. Cells organize themselves into
tube-like structures by changing their shape and establishing
contacts to neighboring cells, but they do not proliferate signif-
icantly during tube formation.
Inhibition of Cdk5 impaired endothelial cell sprouting out of
aortic rings (Fig. 3A). By applying chorioallantoic membrane
assays, we found a strong induction of vessel formation by
VEGF, which was completely blocked upon inhibition of Cdk5
(Fig. 3B). Themouse corneamicropocket assay demonstrated a
pronounced reduction of basic FGF-induced neovasculariza-
tion in vivo (Fig. 3C) upon intraperitoneal administration of
roscovitine (100 mg/kg/day).
Cdk5 Is Required for Endothelial Cell Migration—To verify
the function of Cdk5 in angiogenesis, Cdk5 was specifically
down-regulated using RNAi. Two different approaches were
FIGURE 6. Cdk5 regulates the formation of lamellipodia. A and B, inhibition of Cdk5 using rosc (30 M) or
Cdk5 siRNA reduces the formation of lamellipodia during migration. co indicates untreated cells. A, migrating
HUVECs stained for F-actin (n  3). B, migrating cells stained with anti-cortactin antibodies (n  3). C, Cdk5
localizes to lamellipodia. Images represent HUVECs overexpressing Cdk5-eGFP during spreading (left panel)
and migration (right panel), respectively (each n 3).
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used: silencing of Cdk5 with siRNA (nucleofection) and down-
regulation of Cdk5 using shRNA (adenoviral transfer). In
scratch assays, Cdk5 siRNA reduced the migration of HUVECs
by 40%. In contrast, the silencing of Cdk2, another prominent
target of roscovitine, showed no significant effect (Fig. 4A) (13).
Successful down-regulation of the proteins was determined
24 h after transfection, and no cross-reactionwas observed (Fig.
4B). The viability of cells transfected with Cdk5 siRNA was not
changed (CellTiter-Blue assay, Fig. 4C). Down-regulation of
Cdk5 by shRNA resulted in a very similar effect; by applying
scratch assays, cells treated with Cdk5 shRNA showed a
reduced migration by 49% (Fig. 4D). Cdk5 shRNA also signifi-
cantly reduced the euclidean distance of HUVECs in a chemo-
tactic gradient (Fig. 4E), suggesting a defective chemokinesis
(loss of orientation). Fig. 4F shows successful knockdown of
Cdk5 with shRNA.
To find out whether Cdk5 kinase activity is required for
endothelial cell migration, we examined migration of HUVECs
overexpressing wild-type Cdk5 (Cdk5-wt) or a dominant-neg-
ative mutant Cdk5-D145N (Cdk5-dn) in comparison with
HUVECs overexpressing the empty vector (pCMV-neo-Bam)
serving as control. Overexpression
of dominant-negativeCdk5 (kinase-
dead Cdk5-D145N) reduced migra-
tion by 46%, an extent similar to
RNAi experiments. The Western
blot shows overexpression of the
respective Cdk5 mutants (Fig. 4G).
Cdk5 Does Not Influence Cell
Adhesion and Microtubules—Inhi-
bition and silencing of Cdk5 re-
duced the phosphorylation of FAK
at Ser-732. The autophosphor-
ylation site of FAK at tyrosine 397
was not affected (Fig. 5, A and B).
The functional impact of inhibition
of Cdk5 on focal adhesion dynamics
and adhesion as well as microtubule
organization of HUVECs has been
analyzed. Focal adhesions were
visualized by overexpressing eYFP-
vinculin. Inhibition of Cdk5 did not
change focal adhesion structure
(maturation) and dynamics during
cell spreading (Fig. 5C). Further-
more, cell adhesion on various sub-
strates was not affected (Fig. 5D).
Moreover, no effect of Cdk5 inhi-
bition on the structure of the tubu-
lin cytoskeleton in migrating
HUVECs was found (Fig. 5E). To
analyze microtubule dynamics, we
overexpressed eGFP-CLIP-170.
Treatment with roscovitine nei-
ther changed microtubule dynam-
ics (Fig. 5F) nor had any influence
on the polymerization of tubulin
in contrast to classical tubulin-tar-
geting compounds such as taxol, which stabilizes microtu-
bules, or vinblastine, which causes fragmentation of micro-
tubules (Fig. 5G).
Cdk5 Influences the Actin Cytoskeleton—The influence of
Cdk5 on the actin cytoskeleton in endothelial cells was exam-
ined by analyzing F-actin distribution in migrating cells.
Untreated cells and cells treated with nt siRNA formed lamel-
lipodia with a densely packed actin seam at the leading edge
(Fig. 6A, upper panels), in contrast to cells treated with rosco-
vitine or Cdk5 siRNA (Fig. 6A, lower panels). In addition, the
inhibition of Cdk5 reduced the localization of cortactin, a
lamellipodialmarker, to the leading edge ofmigrating cells (Fig.
6B) (14). Overexpression of Cdk5-eGFP in HUVECs demon-
strated the localization of Cdk5 to lamellipodia during cell
spreading (Fig. 6C, left panel; supplemental video 2) and cell
migration (Fig. 6C, right panel; supplemental video 3), suggest-
ing a function of Cdk5 in the formation of lamellipodia.
Cdk5 Regulates the Activity of RhoA and Rac1—In pulldown
assays, inhibition or down-regulation of Cdk5 increased levels
of GTP-bound active RhoA (Fig. 7,A and B), accompanied by a
decrease of p27kip1 protein expression (Fig. 7, C and D). In
FIGURE 7. Cdk5 influences the p27kip/RhoA pathway. A, inhibition of Cdk5 increases the amount of active
GTP-bound RhoA (RhoA-GTP). Total RhoA serves as loading control (n  3). co indicates untreated cells.
B, knockdown of Cdk5 with shRNA (Cdk5 shRNA) increases the amount of RhoA-GTP in comparison with cells
treated with nt shRNA. Total RhoA serves as loading control (n  3). C, inhibition of Cdk5 decrease p27kip1
protein expression. Cells were either left untreated or treated with rosc (30M, n 3).D, p27kip1 expression of
HUVECs transfected with Cdk5 siRNA or with nt siRNA, respectively, is shown (n  3). E, preincubation with
Y27632 (Y, 10 M) does not significantly abolish the effect of rosc (10 and 30 M) on HUVEC migration. Repre-
sentative images show migrating cells treated as indicated. The bar graph shows the quantitative evaluation
(one-way ANOVA/Holm-Sidak, n 3). n.s., not significant.
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scratch assays, preincubation with the Rho-associated protein
kinase (ROCK) inhibitor Y27632 (Y) could not significantly
compensate for the inhibition of migration upon treatment
with roscovitine (Fig. 7E).
The activity of Rac1 was dramatically decreased upon inhi-
bition and knockdown of Cdk5 (Fig. 8, A and B). Furthermore,
inhibition or down-regulation of Cdk5 abolished the localiza-
tion of Rac1 and its effector cortactin to the leading edge of
migrating cells (Fig. 8, C and D). In live cell imaging experi-
ments with cells overexpressing Rac1-eYFP, untreated cells
showed a regular cell shape with Rac1 localized to the cell
periphery (Fig. 8E, upper panel; supplemental video 4). Inhibi-
tion of Cdk5 caused a distribution of Rac1 over the whole cell,
accompanied by an irregular cell shape and an irregular forma-
tion of ruffles (Fig. 8E, lower panel; supplemental video 5). In
scratch assays, overexpression of a constitutively active Rac
mutant (Rac V12) compensated for the inhibition of HUVEC
migration upon down-regulation of Cdk5 by shRNA (Fig. 8F).
DISCUSSION
In the present study, we demonstrate a crucial role of Cdk5 in
the regulation of endothelial cell migration and angiogenesis. We
identify the Cdk5 inhibitor roscovitine as antiangiogenic com-
pound and propose Cdk5 as the target of roscovitine responsible
for its antiangiogenic effects.We provide information concerning
the signaling of endothelial Cdk5 suggesting that Cdk5 regulates
endothelial cell migration via the small GTPase Rac1.
Roscovitine (Seliciclib, CYC202) is a well established Cdk
inhibitor, classically developed to control cell proliferation. It
has anticancer activity and is currently being evaluated in a phase
2b clinical trial concerning cancer therapy (“Efficacy Study
of Oral Seliciclib to Treat Non-Small Cell Lung Cancer”).3
We show that roscovitine functionally blocks angiogenesis in
vitro and in vivo. Roscovitine does not selectively inhibit one
specific Cdk (13). It was used as a tool to get first impressions
about a potential function of Cdks in angiogenesis.
We propose that Cdk5 is the target of roscovitine responsible
for its antiangiogenic effects. By selectively down-regulating
Cdk5 using RNAi and by overexpressing a kinase-dead Cdk5
mutant, we identify Cdk5 activity as key for the effects on EC
migration. Cdk5 classically is known to regulate neuronal pro-
cesses, and only recently, some reports investigated the role of
Cdk5 in cancer cells (15–19). This is the first study that charac-
terizes the function of Cdk5 in the context of angiogenesis.
Our results suggest a new therapeutic indication of roscovi-
tine and Cdk5 inhibitors in general as antiangiogenic agents. A
probable antiangiogenic application of Cdk5 inhibitors might
represent a therapeutic benefit to broaden the spectrum and to
overcome the drawbacks of already existing inhibitors of angio-
genesis in oncology and other pathological processes involving
excessive angiogenesis. Increased invasiveness of cancer cells in
response to antiangiogenic therapy has just recently been iden-
tified as a resistance mechanism to escape nutrient and oxygen
deprivation (20–22). In this respect, roscovitine could be of
dual benefit as it inhibits both metastasis and angiogenesis (19,
23). Moreover, the inhibition of Cdk5 blocked angiogenesis
independently of the pro-angiogenic stimulus used. Thus, the
regulation of Cdk5 in the endothelium via one specific growth
factor is rather unlikely. This turns Cdk5 into a highly attractive
target for antiangiogenic therapy as endothelial cells are able to
adapt to antiangiogenic treatment with VEGF inhibitors by up-
regulating alternative signaling circuits (2).
Ourmechanistic studies implicate that Cdk5 regulates endo-
thelial cell migration via the actin cytoskeleton. We investi-
gated the effects of Cdk5 on cell adhesion, the microtubules,
and the actin cytoskeleton, which represent the three central
elements regulated during migration (24).
The inhibition of Cdk5 influenced neither cell adhesion nor
focal adhesions. This might be surprising as the phosphoryla-
tion of FAK at Ser-732 is decreased upon inhibition or down-
regulation of Cdk5. A possible explanation might be that FAK
kinase activity is not dependent on the phosphorylation at Ser-
732 (25). Tyr-397, the initial FAK autophosphorylation site, is
not changed upon inhibition of Cdk5.Moreover, the role of the
phosphorylation of FAK at Ser-732 in ECmigration is not com-
pletely clear. In endothelial cells, Ser-732 of FAK was reported
to regulate centrosome function during mitosis. The authors
suggest that Ser-732 phosphorylation of FAK is crucial for FAK
regulation of proliferation and tubulogenesis but not of migra-
tion of endothelial cells (26). In contrast, FAK has also been
shown to be phosphorylated at Ser-732 by ROCK in ECs, which
triggers the formation of ventral focal adhesions andplays a role
in VEGF-induced ECmigration (27). In our system, besides the
decreased phosphorylation of FAK at Ser-732, we found an
increase of active RhoA, the most prominent activator of
ROCK, upon inhibition/down-regulation of Cdk5. If one con-
siders that ROCK induces the phosphorylation of FAK at Ser-
732, one would expect an increased phosphorylation of FAK at
Ser-732 upon increased RhoA. This discrepancy might be a
result of the complex interplay between FAK and Rho-GT-
Pases. Another study shows that Cdk5 regulates epithelial cell
adhesion, cytoskeletal contraction, and migration via modulat-
ing RhoA activity by suppressing Src and p190RhoGAP. In con-
trast to our findings, this work shows a decrease of active RhoA
3 Belani, C. (2006) Efficacy Study of Oral Seliciclib to Treat Non-small Cell Lung
Cancer (ClinicalTrials.gov, identifier NCT00372073).
FIGURE 8. Cdk5 influences Rac1. A, inhibition of Cdk5 with rosc (30 M) reduces the amount of active GTP-bound Rac1. Total Rac1 serves as loading control
(n 3). co indicates untreated cells. B, knockdown of Cdk5with shRNA (Cdk5 shRNA) decreases the amount of Rac1-GTP in comparisonwith cells treatedwith
nt shRNA. Total Rac1 serves as loading control (n  3). C and D, rosc (30 M) as well as Cdk5 siRNA inhibit localization of Rac1 (green) and cortactin (red) to
lamellipodia of migrating endothelial cells. Untreated cells (co) or nt siRNA-treated cells serve as the respective controls (n  3). E, during cell spreading,
inhibition of Cdk5 abrogates the localization of Rac1 to the cell periphery. Representative images display cells overexpressing Rac1-eYFP during spreading
untreated or treated with rosc (30M), respectively (n 3). F, overexpression of constitutively active Rac1 (Rac V12) compensates for themigration-inhibiting
effect of Cdk5 knockdown. Upper panels, in scratch assays, knockdown of Cdk5 with shRNA significantly reduces migration of cells treated with the empty
vector (pcDNA3). In HUVECs overexpressing constitutive active Rac1 (Rac V12), treatment with Cdk5 shRNA does not reducemigration. The bar graphs display
the quantitative evaluation (pcDNA3, rank sum test, *, p 0.05, n 5; Rac V12, rank sum test; n 5). Lower panels, theWestern blots show the knockdown of
Cdk5 by shRNA and overexpression of Myc-tagged Rac V12. n.s., not significant.
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concomitant to an increasedmigration upon inhibition ofCdk5
(28). Talin is another target of Cdk5 that regulates focal adhe-
sions and migration of neuroblastoma cells. Cdk5-dependent
phosphorylation of the talin head domain at Ser-425 prevents
its ubiquitylation and degradation, controlling adhesion stabil-
ity and cell migration (23).
Nonetheless, because we found no change of focal adhesions
or cell adhesion upon inhibition of Cdk5, we searched for a
different target of Cdk5 in endothelial cell migration. We also
did not find any effect of Cdk5 on microtubules, although Ser-
732 phosphorylation on FAK previously has been shown to
influence microtubule organization, nuclear movement, and
neuronal migration (25). Thus, we propose a specific signaling
of Cdk5 in the vasculature.
We identify the actin cytoskeleton to be the relevant target of
Cdk5 in endothelial cell migration. Endothelial Cdk5 regulates
the formation of lamellipodia, actin-based structures that are
essential for cell migration (29). Our findings are in line with
reports concerning the function of Cdk5 in neurons. Neuronal
Cdk5 affects the actin cytoskeleton by phosphorylating p27kip
and PAK1 as well as Neurabin-I (25, 30, 31); it controls den-
dritic spine morphology via phosphorylation of the RhoA gua-
nine-nucleotide exchange factor (GEF) ephexin1 (32); and
it phosphorylates the actin-binding proteins WAVE1 and
WAVE2 (33, 34).
The small Rho GTPases RhoA and Rac1 represent the most
prominent regulators of the actin cytoskeleton (35, 36). We
found that inhibition of Cdk5 increased RhoA activity, con-
comitant to a decrease of p27kip1 protein level. This parallels
findings in neurons, where Cdk5 has been shown to phosphor-
ylate and stabilize p27kip1, suppressing RhoA activity and
increasing activated cofilin, which regulates actin turnover (31).
The migration defect of p27kip1-null fibroblasts is rescued by
the inhibition of ROCK, the most prominent downstream
effector of RhoA (38). In endothelial cells, in contrast, blockade
of ROCK could not compensate for the antimigratory effect of
roscovitine. Thus, although Cdk5 indeed modulates RhoA
activity, it seems not to regulate endothelial cell migration pri-
marily via the p27kip1/RhoA/ROCK pathway. In the context of
epithelial cell migration, Cdk5 was described as a regulator of
RhoA activity and cytoskeletal contraction. In contrast to our
findings, in epithelial cells, inhibition of Cdk5 blocks RhoA-
ROCK signaling and increases migration (28). The discrepan-
cies concerning the different effects of Cdk5 on the activity of
RhoA and the distinct functional consequencesmight be due to
the diverse cell types and suggest a specific signaling of Cdk5 in
the endothelium.
Our data indicate Rac1 to be the most likely link between
Cdk5 function and endothelial cell migration. We show that
inhibition or down-regulation of Cdk5 dramatically reduces
Rac1 activity and impairs the localization of Rac1 and its effec-
tor cortactin, a regulator of the protrusion and integrity of
lamellipodia, to the cell membrane (39). Constitutively active
Rac1 compensates for the migration-inhibiting effect of the
knockdown of Cdk5. Thus, we propose that Cdk5 exerts its
effects in endothelial cell migration via Rac1. This can be inter-
preted contrariwise to the report of Nikolic and colleagues (30),
where neuronal Cdk5 has been elucidated as a downstream
effector of Rac1. A different andmuchmore interesting probable
explanationmight be a feedback loop betweenCdk5 andRac1. As
a kinase, Cdk5 might regulate Rac1 by the phosphorylation of a
guanine nucleotide exchange factor, a GTPase-activating pro-
tein (GAP), or a GDP dissociation inhibitor (GDI) for Rac1,
respectively. Neuronal Cdk5 was shown to phosphorylate var-
ious regulators of Rac1. Cdk5-mediated phosphorylation of
RasGRF2 down-regulates the activity of Rac1, and the regula-
tion of Trio and Kalirin by Cdk5 activates Rac1 (40–42). By
phosphorylating ezrin, Cdk5 was shown to modulate RhoGDI,
inhibitingRac1 (43). The fact thatCdk5 seems to be able to both
increase and decrease the activity of Rac1 and, on the contrary,
to be regulated by Rac1 suggests that the function of Cdk5
strongly depends on the cellular system and/or on the func-
tional context, respectively.
Our work clearly elucidates a vascular function of Cdk5.
Consequently, one would expect a vascular phenotype of Cdk5
knock-out mice. However, vascular or cardiac defects of these
mice are not described. According to the crucial function of
Cdk5 in the nervous system, Cdk5 knock-outmice show abnor-
mal corticogenesis and neuronal defects and die perinatally
(44). Mice exhibiting vascular phenotypes often die during
embryogenesis (45, 46) or show neonatal lethality (37), depend-
ing on the severity of the phenotype. Tomake use of endothelial
specific Cdk5 knock-outmicemight provide the opportunity to
study the function of Cdk5 in the endothelium in vivo.
In conclusion, this study for the first time presents a novel
and crucial function of Cdk5 in endothelial cell migration, elu-
cidates a specific signaling of endothelial Cdk5, and highlights
Cdk5 as a promising target for antiangiogenic therapy.
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